What’s Next for Nektar Therapeutics?
Nektar Therapeutics (NASDAQ: NKTR) has a lot on its plate. The company's advancing its lead drug candidate, NKTR-181, to the FDA for use in chronic pain and its pipeline crisscrosses immuno-oncology and immunology. Shares of Nektar Therapeutics have been on a roll lately, but can its winning streak continue rewarding investors?
In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes and Todd Campbell explain why investors are flocking to include this biotech stock in portfolios.
A full transcript follows the video.
Source: Fool.com
Nektar Therapeutics Stock
€1.25
3.710%
Currently there is a rather positive sentiment for Nektar Therapeutics with 4 Buy predictions and 1 Sell predictions.
With a target price of 2 € there is a hugely positive potential of 59.74% for Nektar Therapeutics compared to the current price of 1.25 €.
